Apogee Therapeutics, Inc. 8-K

What Happened
Apogee Therapeutics on May 27, 2026 announced positive 16‑week induction dose‑optimization results from Part B of its Phase 2 APEX trial of zumilokibart (APG777) in adult patients with moderate‑to‑severe atopic dermatitis (AD). In the randomized, placebo‑controlled Part B, 346 adults were dosed after 1:1:1:1 randomization to high, mid, low dose or placebo. The trial met its primary endpoint (EASI‑75 at Week 16): high‑dose 61.6%, mid‑dose 65.9%, low‑dose 50.5% vs placebo 23.4% (all p<0.001). The company highlighted the mid‑dose as the planned Phase 3 dose and reported strong mid‑dose secondary results (IGA 0/1 46.0% vs 10.9% placebo; EASI‑90 47.4% vs 9.3%; I‑NRS ≥4 reduction 50.5% vs 13.9%; EASI‑100 16.5% vs 3.4%; vLDA 20.6% vs 4.5%; statistical significance cited).

Key Details

• Trial size & design: 346 adults randomized 1:1:1:1 (high/mid/low/placebo); primary endpoint EASI‑75 at Week 16.
• EASI‑75 results (Week 16): High 61.6%, Mid 65.9%, Low 50.5%, Placebo 23.4% (p<0.001 vs placebo for each dose).
• Mid‑dose secondary outcomes (Week 16): IGA 0/1 46.0% vs 10.9% placebo (p<0.001); EASI‑90 47.4% vs 9.3% (p<0.001); I‑NRS ≥4 reduction 50.5% vs 13.9% (p<0.001).
• Safety: Generally well tolerated; most common TEAEs nasopharyngitis, headache, noninfective conjunctivitis. Conjunctivitis pooled rates — mid‑dose 10.6%, low 15.1%, high 20.7%.
• Development plan: Apogee plans to initiate Phase 3 ADventure 1 & 2 (monotherapy) and ADventure TCS (with topical corticosteroids) using the mid‑dose in 2H 2026, pending regulatory interactions; launch target ~2029. Other programs include Phase 2b asthma (ASPIRE) expected 1H 2027 and Phase 2a EoE (ELEVATE) expected 2H 2026.

Why It Matters
These Phase 2 Part B results provide clinical evidence supporting Apogee’s mid‑dose choice for Phase 3 and justify plans to start replicate Phase 3 trials in AD in the second half of 2026. For investors, the data show meaningful efficacy vs placebo on key AD endpoints (EASI‑75, IGA, EASI‑90, itch reduction) with a safety profile described as consistent with the anti‑IL‑13 class; however, regulatory interactions and Phase 3 success are still required before approval or commercialization. The filing also sets a clear development timeline (AD, asthma, EoE) and a 2029 launch target — all forward‑looking plans the company notes are subject to risks and regulatory review.